
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF326 (zinc finger protein 326) encodes a zinc finger protein that interacts with the RNA polymerase II complex and participates in transcriptional elongation and RNA splicing. It is a component of the DBIRD complex and is localized to the nucleoplasm, linking transcriptional regulation with pre-mRNA processing.
NCI-H1299 is a human non-small cell lung cancer cell line established from a lymph node metastasis of the lung from a patient who had previously received radiation therapy. The cell line represents a metastatic lung cancer model and is commonly used in studies of lung cancer biology, tumor progression, and molecular mechanisms underlying cancer development.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 4
Reference Transcript: NM_182976
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?